ISSN: 2161-1149 (Printed)
Christine Konya and Vasileios C Kyttaris
T cells play a central role in Systemic Lupus Erythematosus (SLE) pathogenesis. The discovery of key steps that lead to SLE T cell dysfunction allowed several investigators to propose targeted treatments for SLE. Herein, we discuss the potential of novel drugs targeting SLE T cells, such as fostamatinib and anti-IL-17 antibodies. Furthermore, we discuss the use of already approved medications such as rapamycin, dipyridamole and N acetylcysteine as targeted therapies for SLE.